NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Return
20.18%
This Quarter Return
-1.68%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$120M
AUM Growth
+$37.7M
(+46%)
Cap. Flow
+$39.9M
Cap. Flow
% of AUM
33.26%
Top 10 Holdings %
Top 10 Hldgs %
71.57%
Holding
35
New
11
Increased
11
Reduced
1
Closed
12
Top Buys
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$11.2M |
| 2 |
Coherus Oncology, Inc. Common Stock
CHRS
|
+$6.99M |
| 3 |
Ascendis Pharma
ASND
|
+$6.94M |
| 4 |
Pacira BioSciences
PCRX
|
+$6.48M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$5.77M |
Top Sells
| 1 |
Heron Therapeutics
HRTX
|
+$9.5M |
| 2 |
Bausch Health
BHC
|
+$5.08M |
| 3 |
STML
Stemline Therapeutics, Inc.
STML
|
+$4.18M |
| 4 |
Novartis
NVS
|
+$3.83M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$2.79M |
Sector Composition
| 1 | Healthcare | 92.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $12.1M | 10.1% |
152,441
+140,489
| +1,175% | +$11.2M |
|
2
Insmed
INSM
$30.8B
| $12.1M | 10.04% |
470,741
+186,478
| +66% | +$4.77M |
|
|
BOLD
3
DELISTED
Audentes Therapeutics, Inc
BOLD
| $11.1M | 9.27% |
294,013
+43,393
| +17% | +$1.64M |
|
|
4
Neurocrine Biosciences
NBIX
$14.1B
| $7.8M | 6.5% |
92,380
+68,340
| +284% | +$5.77M |
|
5
Sarepta Therapeutics
SRPT
$1.82B
| $7.65M | 6.37% |
50,317
+29,047
| +137% | +$4.41M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $7.49M | 6.23% |
142,305
+55,206
| +63% | +$2.9M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $7.27M | 6.06% |
524,140
+189,416
| +57% | +$2.63M |
|
|
8
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $6.99M | 5.82% |
+316,316
| New | +$6.99M |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $6.94M | 5.78% |
+60,266
| New | +$6.94M |
|
|
10
Pacira BioSciences
PCRX
$1.22B
| $6.48M | 5.4% |
+149,086
| New | +$6.48M |
|
11
UroGen Pharma
URGN
$869M
| $6.36M | 5.29% |
176,866
+44,277
| +33% | +$1.59M |
|
12
uniQure
QURE
$904M
| $4.68M | 3.9% |
59,883
+21,083
| +54% | +$1.65M |
|
|
AMRN
13
Amarin Corp
AMRN
$310M
| $4.47M | 3.72% |
11,515
+4,080
| +55% | +$1.58M |
|
14
AbbVie
ABBV
$386B
| $3.83M | 3.19% |
+52,681
| New | +$3.83M |
|
|
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.77M | 3.14% |
+86,165
| New | +$3.77M |
|
16
Viatris
VTRS
$11.6B
| $1.95M | 1.63% |
+102,560
| New | +$1.95M |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.87M | 1.55% |
+143,665
| New | +$1.87M |
|
18
Regeneron Pharmaceuticals
REGN
$59.4B
| $1.77M | 1.48% |
+5,668
| New | +$1.77M |
|
19
Madrigal Pharmaceuticals
MDGL
$9.63B
| $1.62M | 1.35% |
15,423
+11,971
| +347% | +$1.25M |
|
|
DERM
20
DELISTED
Dermira, Inc.
DERM
| $1.32M | 1.1% |
+138,102
| New | +$1.32M |
|
21
Gilead Sciences
GILD
$142B
| $1.26M | 1.05% |
+18,697
| New | +$1.26M |
|
22
AnaptysBio
ANAB
$655M
| $679K | 0.57% |
+12,026
| New | +$679K |
|
|
AGN
23
DELISTED
Allergan plc
AGN
| $560K | 0.47% |
3,347
-10,353
| -76% | -$1.73M |
|
|
24
Novartis
NVS
$240B
| – | – |
-50,587
| Closed | -$3.83M |
|
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| – | – |
-6,200
| Closed | -$986K |
|